Bernstein SocGen Group HC specialist Christian Moore reiterated an Outperform rating and $410.00 price target on Stryker (NYSE: SYK).

The analyst commented: "Another large-cap + high-quality stock to put on your radar on a buying opportunity here is SYK – over the last year, its forward multiple has been cut in a third, despite fundamentals holding up very well in a non-controversial name amidst many controversies in the space. The >6% down-move on Friday was crazy and likely non-fundamentally driven for a quarter that was messy due to a cyber-attack that sell-side previews did not adequately account for. From here, the Street’s +8.7% organic growth for 2Q looks like a complete lay-up (will easily do DD+ growth given the backlog and early feedback on April trends), despite the perception of how much of a step-up this is from the +2.4% in 1Q (this special situation creates opportunity). Also see SYK as an accelerated share-gainer with prolonged issues at ZBH from sales force restructuring and coming sales force defections at JNJ into and around its Ortho spin (likely in early-2027)."

For an analyst ratings summary and ratings history on Stryker click here. For more ratings news on Stryker click here.

Shares of Stryker closed at $294.73 yesterday.